Home > Category > Signaling Pathways > Protein Tyrosine Kinase/RTK > Axl > Bemcentinib | R428 | BGB324

Bemcentinib | R428 | BGB324

ChemLeader 98+%

Catalog No：CL1245 CAS No.：1037624-75-1 MDLNo： Formula：C30H34N8 MW：506.64

Collect Share

Size	Availability	Price(USD)	VIP Price (USD)	Quantity
5 mg	In-stock	$188.00	Visible after login	- +
10 mg	In-stock	$366.00	Visible after login	- +

Chemical safety data sheet(MSDS)

Download MSDS

Certificate Of Authenticity(CPA)

Download COA

Inquiry Add To Cart

Product Overview
Related documents
Product details
Related literature

Product Overview

Product Name	Bemcentinib \| R428 \| BGB324
CAS	1037624-75-1
Formula	C30H34N8
MW	506.64
Appearance	Off-white to yellow powder
Storage condition	Dry, dark and at 0 - 4 ℃ for short term (days to weeks) or -20 ℃ for long term (months to years).

Product details

Bemcentinib (formerly known as BGB324; R428) is a novel, potent and selectiveinhibitor of the RTK (receptor tyrosine kinase) Axl with potential anticancer activity.

Related literature

Human cutaneous melanomas lacking MITF and melanocyte differentiation antigens express a functional Axl receptor kinase.

PMID: 21796150 DOI: 10.1038/jid.2011.218

Read more

R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer.

PMID: 20145120 DOI: 10.1158/0008-5472.CAN-09-2997

Read more

Growth arrest-specific protein 6 receptor antagonism impairs adipocyte differentiation and adipose tissue development in mice.

PMID: 21285281 DOI: 10.1124/jpet.110.178046

Read more

Related

Sorry, no related items

History

Everolimus | RAD-001

159351-69-6 98+%

Rilpivirine Hydrochloride | TMC-278 hydrochloride

700361-47-3 98+%

2,4-Dihydroxy-7-methoxy-2H-benzo[b][1,4]oxazin-3(4H)-one; DIMBOA

15893-52-4 98+%

Bemcentinib | R428 | BGB324

1037624-75-1 98+%

Tamarixetin | 4'-O-Methyl Quercetin

Anlotinib Dihydrochloride (AL3818 Dihydrochloride); Anlotinib 2HCl

1360460-82-7 98+%

Mogamulizumab (Anti-CCR4 / CD194)

1159266-37-1 95+%

Imgatuzumab (Anti-ERBB1 / EGFR / HER1)

959963-46-3 95+%